skip to main content

Bell V-280 Valor cleared to enter engineering and manufacturing development phase

By Zach Rosenberg |

The V-280 Valor tiltrotor demonstrator, photographed in 2021. The tiltrotor has been cleared to enter its initial manufacturing phase. (Bell Helicopter)

The US Army has approved the Bell V-280 Valor to enter the engineering and manufacturing development (EMD) phase, clearing the way for work on the prototype and low-rate initial production (LRIP), according to a 2 August release by the service. The approval follows a preliminary design review (PDR) completed in April.

“This an important step for FLRAA [Future Long-Range Assault Aircraft] and demonstrates the army's commitment to our highest aviation modernisation priority,” said Doug Bush, assistant secretary of the army for acquisition, logistics, and technology, referring to the tiltrotor by its army programme name, FLRAA. “FLRAA will provide assault and medevac [medical evacuation] capabilities for the future army, adding significantly increased speed, range, and endurance.”

Bell is set to build six prototypes for testing; the first is scheduled to fly in 2026. LRIP aircraft are scheduled for production in 2028, and the type's entry into service is expected in 2030.

The army selected the V-280 in December 2022 to replace the Sikorsky UH-60 as the service's main assault, medevac, and utility rotorcraft. While the initial contract is worth USD7.1 billion, follow-on procurements could be worth up to USD70 billion.

“The FLRAA Milestone B decision is another successful step of a deliberate modernisation effort by the army,” said Brigadier General Cain Baker, director for the Future Vertical Lift Cross Functional Team. “The many stakeholders, including academia and industry, have worked hard to ensure rigorous technology development and demonstration and have informed FLRAA requirements and affordability. FLRAA's speed, reach, and survivability will be key to transforming US Army manoeuvre.”

For more information, please see

Looking to read the full article?

Gain unlimited access to Janes news and more...